Focused On-demand Library for Lymphocyte cytosolic protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q13094

UPID:

LCP2_HUMAN

Alternative names:

SH2 domain-containing leukocyte protein of 76 kDa; SLP-76 tyrosine phosphoprotein

Alternative UPACC:

Q13094; A8KA25; Q53XV4

Background:

Lymphocyte cytosolic protein 2, also known as SH2 domain-containing leukocyte protein of 76 kDa or SLP-76 tyrosine phosphoprotein, plays a crucial role in T-cell antigen receptor mediated signaling. This protein's involvement is pivotal for the proper functioning of the immune system, facilitating the communication between cells that is essential for mounting an effective immune response.

Therapeutic significance:

Immunodeficiency 81, a disorder characterized by recurrent infections and immune cell dysfunction, is directly linked to variants affecting the gene encoding Lymphocyte cytosolic protein 2. This connection underscores the protein's critical role in immune system regulation and highlights its potential as a target for therapeutic intervention in immune-related disorders.